Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.
Patrick Connor Johnson, MD
Advertisement
Articles by Patrick Connor Johnson, MD
Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
T-DXd Wins EU Approval for Previously Treated, HER2+ Metastatic Solid Tumors
2
Elisrasib Yields Durable Responses in Pretreated KRAS G12C–Mutant NSCLC Regardless of Prior G12C Inhibitor Use
3
FDA Issues CRL to PET Diagnostic Imaging Kit for Gallium-68 Edotreotide in SSTR+ NETs
4
Dr Thomas on the Efficacy of First-Line Ipatasertib Plus Pembrolizumab in HNSCC
5